IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q.
Wee ZN, et al. Among authors: yu q.
Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746.
Nat Commun. 2015.
PMID: 26503059
Free PMC article.